For families navigating autism spectrum disorder, the journey is lengthy and arduous, often marked by uncertainty, fragmented care, long waits to see specialists, and limited treatment options, coupled with an urgency to act during the most important early childhood development years.
Learn About Our MissionCM-AT is a pre-registrational high-protease enzyme replacement therapy designed for children with low levels of chymotrypsin. By replenishing chymotrypsin and improving protein digestion, CM-AT increases tryptophan availability for brain-serotonin synthesis during early childhood development.
Explore Our Drug Development Approach
Curemark is a late-stage, clinical biopharmaceutical company developing therapies for the treatment of serious neurodevelopmental and neurodegenerative disorders, with CM-AT as the lead asset. The company’s pipeline is built upon a proprietary enzyme replacement technology that biologically addresses the gut-brain pathway connection of many neurological diseases.
Autism Spectrum Disorder (ASD) is a heterogeneous neurodevelopmental condition that affects cognition, language, communication, and social behavior. ASD presents differently in every child, creating a wide range of challenges and support needs. The rising prevalence of ASD with no safe, frontline approved therapies, as well as the increasing demand for early treatment and continuous care, places significant pressure on families and healthcare systems.
CM-AT is a pre-registrational, orally delivered high-protease enzyme replacement therapy being developed by Curemark for children with autism spectrum disorder ages 3 through 8. It is designed to restore a critical step in the gut-brain pathway by replenishing chymotrypsin, an enzyme responsible for liberating essential amino acids from dietary proteins implicated in brain development including tryptophan, phenylalanine, and methionine. By improving protein digestion and raising tryptophan availability, more of the protein crosses the blood-brain barrier and is the sole precursor for brain serotonin synthesis. Serotonin is a neurotransmitter that supports early brain development and enhances protein digestion.
CM-AT has not been approved by regulatory authorities.
Curemark is a neuroscience-focused, late-stage, private biotechnology company dedicated to advancing innovative therapies for neurological and neurodevelopmental disorders. The company’s lead asset, CM-AT, reflects its commitment to developing therapies that address underlying biological pathways and unmet patient needs.
Yes. In addition to CM-AT for Autism Spectrum Disorder, Curemark has additional development programs targeting attention deficit and hyperactivity disorder (ADHD), Parkinson’s disease, and schizophrenia. These programs are based on the company’s broader technology platform.